Reynoutrin
(Synonyms: 槲皮素-3-D-木糖甙,Quercetin-3-D-xyloside; Reinutrin) 目录号 : GC34758
A flavonoid glycoside with diverse biological activities
Cas No.:549-32-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Quercetin 3-O-β-D-xylopyranoside is a flavonoid glycoside that has been found in N. candida and has diverse biological activities.1,2,3 It reduces malondialdehyde (MDA) levels in isolated rat brain when used at a concentration of 10 ?g/ml.1 Quercetin 3-O-β-D-xylopyranoside (10, 50, and 100 ?g/ml) reduces LPS- and cerulein-induced increases in reactive oxygen species (ROS) production and levels of GRP78, a marker of endoplasmic reticulum stress, in an AR42J rat pancreatic acinar cell model of pancreatitis.2 In vivo, quercetin 3-O-β-D-xylopyranoside (12.5, 25, and 50 mg/kg) decreases serum TNF-α and IL-6 levels, myocardial MDA levels, and myocardial fibrosis, as well as improves cardiac function, in a rat model of ischemic heart failure.3
1.Liu, R.-N., Wang, W., Ding, Y., et al.A new flavonol glycoside and activity of compounds from the flower of Nymphaea candidaJ. Asian Nat. Prod. Res.9(3-5)333-338(2007) 2.Seo, J.Y., Pandey, R.P., Lee, J., et al.Quercetin 3-O-xyloside ameliorates acute pancreatitis in vitro via the reduction of ER stress and enhancement of apoptosisPhytomedicine5540-49(2019) 3.Yang, W., Tu, H., Tang, K., et al.Reynoutrin improves ischemic heart failure in rats via targeting S100A1Front. Pharmacol.12703962(2021)
| Cas No. | 549-32-6 | SDF | |
| 别名 | 槲皮素-3-D-木糖甙,Quercetin-3-D-xyloside; Reinutrin | ||
| Canonical SMILES | O=C1C(O[C@H]2[C@@H]([C@H]([C@@H](CO2)O)O)O)=C(C3=CC=C(O)C(O)=C3)OC4=CC(O)=CC(O)=C14 | ||
| 分子式 | C20H18O11 | 分子量 | 434.35 |
| 溶解度 | DMSO : 150 mg/mL (345.34 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.3023 mL | 11.5115 mL | 23.0229 mL |
| 5 mM | 0.4605 mL | 2.3023 mL | 4.6046 mL |
| 10 mM | 0.2302 mL | 1.1511 mL | 2.3023 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Reynoutrin Improves Ischemic Heart Failure in Rats Via Targeting S100A1
Front Pharmacol 2021 Jul 23;12:703962.PMID:34366855DOI:10.3389/fphar.2021.703962.
This study investigated the effects of Reynoutrin on the improvement of ischemic heart failure (IHF) and its possible mechanism in rats. The rat heart failure model was established by permanently ligating the left anterior descending coronary artery (LAD) and administering different doses of Reynoutrin. Cardiac function, inflammatory factors releasing, oxidative stress, cardiomyocytes apoptosis, and myocardial fibrosis were evaluated. Western blotting was used to determine protein expression levels of S100 calcium-binding protein A1 (S100A1), matrix metallopeptidase 2(MMP2), MMP9, phosphorylated (p-) p65, and transforming growth factor -β1 (TGF-β1) in myocardial tissue of the left ventricle. Results showed that Reynoutrin significantly improved cardiac function, suppressed the release of inflammatory factors, reduced oxidative stress, inhibited cardiomyocytes apoptosis, and attenuated myocardial fibrosis in rats with IHF. In rat myocardial tissue, permanent LAD-ligation resulted in a significant down-regulation in S100A1 expression, whereas Reynoutrin significantly up-regulated S100A1 protein expression while down-regulating MMP2, MMP9, p-p65, and TGF-β1 expressions. However, when S100A1 was knocked down in myocardial tissue, the above-mentioned positive effects of Reynoutrin were significantly reversed. Reynoutrin is a potential natural drug for the treatment of IHF, and its mechanism of action involves the up-regulation of S100A1 expression, thereby inhibiting expressions of MMPs and the transcriptional activity of nuclear factor kappa-B.
Simultaneous quantification of hyperin, Reynoutrin and guaijaverin in mice plasma by LC-MS/MS: application to a pharmacokinetic study
Biomed Chromatogr 2016 Jul;30(7):1124-1130.PMID:26588877DOI:10.1002/bmc.3660.
A specific and sensitive LC-MS/MS assay was developed to simultaneously quantify three structurally similar flavonoid glycosides - hyperin, Reynoutrin and guaijaverin - in mouse plasma. Biosamples were prepared by solid-phase extraction. Isocratic chromatographic separation was performed on an AichromBond-AQ C18 column (250 × 2.1 mm, 5 μm) with methanol-acetonitrile-water-formic acid (20:25:55:0.1) as the mobile phase. Detection of hyperin, Reynoutrin, guaijaverin and internal standard [luteolin-7-O-β-d-apiofuranosyl-(1 → 6)-β-d-glucopyranoside] was achieved by ESI-MS/MS in the negative ion mode using m/z 463 → m/z 300, m/z 433 → m/z 300, m/z 433 → m/z 300 and m/z 579 → m/z 285 transitions, respectively. Linear concentration ranges of calibration curves were 4.0-800.0 ng/mL for hyperin and Reynoutrin and 8.0-1600.0 ng/mL for guaijaverin when 100 μL of plasma was analyzed. We used this validated method to study the pharmacokinetics of hyperin, Reynoutrin and guaijaverin in mice following oral and intravenous administration. All three quercetin-3-O-glycosides showed poor oral absorption in mice, and the absolute bioavailability of hyperin after oral administration of 100 mg/kg was 1.2%. Pretreatment with verapamil increased the peak concentration and area under the concentration-time curve of hyperin, which were significantly higher than the control values. The half-life of hyperin with verapamil was significantly prolonged compared with that of the control. Copyright © 2016 John Wiley & Sons, Ltd.
Clinical Potential of Himalayan Herb Bergenia ligulata: An Evidence-Based Study
Molecules 2022 Oct 18;27(20):7039.PMID:36296631DOI:10.3390/molecules27207039.
Herbal products have been used in traditional systems of medicine and by ethnic healers for ages to treat various diseases. Currently, it is estimated that about 80% of people worldwide use herbal traditional medicines against various ailments, partly due to easy accessibility and low cost, and the lower side effects they pose. Bergenia ligulata, a herb ranging from the Himalayas to the foothills, including the north-eastern states of India, has traditionally been used as a remedy against various diseases, most prominently kidney stones. The medicinal properties of B. ligulata have been attributed to bergenin, its most potent bioactive component. Apart from bergenin, the other compounds available in B. ligulata are arbutin, gallic acid, protocatechuic acid, chlorogenic acid, syringic acid, catechin, ferulic acid, afzelechin, paashaanolactone, caryophyllene, 1,8-cineole, β-eudesmol, stigmasterol, β-sitosterol, parasorbic acid, 3-methyl-2-buten-1-ol, phytol, terpinen-4-ol, tannic acid, isovalaric acid, avicularin, quercetin, Reynoutrin, and sitoinoside I. This review summarizes various medicinal properties of the herb, along with providing deep insight into its bioactive molecules and their potential roles in the amelioration of human ailments. Additionally, the possible mechanism(s) of action of the herb's anti-urolithiatic, antioxidative, antipyretic, anti-diabetic, anti-inflammatory and hepatoprotective properties are discussed. This comprehensive documentation will help researchers to better understand the medicinal uses of the herb. Further studies on B. ligulata can lead to the discovery of new drug(s) and therapeutics for various ailments.
Flavonoids from Prunus serotina Ehrh
Acta Pol Pharm 2005 Mar-Apr;62(2):127-33.PMID:16161354doi
In the course of chemotaxonomic study of the genus Prunus, seven flavonol glycosides were isolated from the leaves of Prunus serotina Ehrh., characterized by UV and NMR spectroscopy, and identified finally as three quercetin monosides: hyperoside, avicularin, Reynoutrin, three quercetin biosides: 3-O-(6"-O-alpha-L-rhamnopyranosyl)-beta-D-glucopyranoside, 3-O-(2"-O-alpha-L-rhamnopyranosyl)-beta-D-glucopyranoside and 3-O-(2"-O-alpha-L-rhamnopyranosyl)-beta-D-galactopyranoside as well isorhamnetin 3-O-(6"-O-alpha-L-rhamnopyranosyl)-beta-D-glucopyranoside. The presence of determined flavonoids in the flowers was confirmed by TLC.
Cytotoxic and anti-diabetic potential, metabolic profiling and insilico studies of Syzygium cumini (L.) Skeels belonging to family Myrtaceae
Nat Prod Res 2022 Feb;36(4):1026-1030.PMID:33146032DOI:10.1080/14786419.2020.1843032.
LC-HR-MS-coupled metabolic profiling of the methanol extracts from different parts of Syzygium cumini (L.), which was extensively identified via DNA fingerprinting, led to dereplication of 24 compounds. Cytotoxic investigation highlighted both extracts as the most potent, against both MCF-7 and MDA-231 Cell lines, with IC50 value of 5.86 ± 0.63 µg/ml and against HCT -116 cell line, with IC50 value of 1.24 ± 0.09 µg/ml, respectively. A molecular docking study was performed on the dereplicated compounds, which highlighted myricetin-3-glucoside (7), myricitrin (12), Reynoutrin (15) and quercitrin (16) as the top scoring ligands within the protein active site (FIH-1). Interestingly, the extracts were significant against streptozotocin-induced diabetes in the order of flowers > seeds > leaves with BGL level of 98.9 ± 4.3, 123.2 ± 4.9 and 132.8 ± 5.9 mg/dl, respectively. The study highlights the health benefits of Syzygium cumini (L.) as a promising cytotoxic source.